SCHEMBL5639612

SCHEMBL5639612

NC(=O)c1cc(C(=O)NCC2CC(=O)N(c3ccc(N4CCCCC4=O)cc3)C2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
HSD17B10 Q99714 1/20 0.46
MAPT P10636 3/20 0.45
POLB P06746 3/20 0.44
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
RECQL P46063 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
PRMT5 O14744 1/20 0.43
F10 P00742 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
BLM P54132 1/20 0.41
HPGD P15428 4/20 0.41
BPTF Q12830 1/20 0.41
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5639753 0.89 MAPT (0.47) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL5640350 0.87 MAPT (0.51) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL4593361 0.85 LMNA (0.65) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL4587447 0.85 LMNA (0.46) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL5644079 0.83 MAPT (0.65) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL4587165 0.83 MAPT (0.46) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL5639667 0.83 HSD17B10 (0.46) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL5641374 0.82 LMNA (0.53) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL4594192 0.82 MAPT (0.53) LMNAHSD17B10MAPTPOLBALDH1A1
SCHEMBL5640706 0.82 LMNA (0.50) LMNAHSD17B10POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 US disclosed
US-20050107361-A1 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMANY 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107361-A1 Monocyclic and bicyclic lactams as factor Xa inhibitors F2, F12, SPINT2 LMNA 774/4885HSD17B10 1275/4885MAPT 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.